Common diabetes drug may shield leg surgery patients from heart attacks and amputations
NCT ID NCT07157475
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a type of diabetes medicine called SGLT-2 inhibitors (or 'flozins') can help prevent serious heart and limb problems in people who have had surgery to open blocked leg arteries. Researchers will compare 300 patients who took the drug after surgery with those who did not, checking for heart attacks, strokes, repeat procedures, or amputations. The goal is to see if this medicine offers extra protection for these high-risk patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE (PAD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wroclaw Medical University
RECRUITINGWroclaw, Lower Silesian Voivodeship, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple walk predict vascular disease? new study investigates
- New ultrasound technique aims to save limbs in artery disease patients
- Tailored blood thinners could save limbs in PAD patients
- Blood test may prevent clots after leg surgery
- Handball therapy: a playful path to better walking for seniors with leg artery disease
- New MRI contrast agent may improve artery blockage detection in legs